Bionano Genomics (BNGO)
NASDAQ:BNGO
Want to see BNGO full AI Analyst Report?
BNGO Stock Chart & Stats
$1.62
-$0.04(-14.25%)
At close: 4:00 PM EST
$1.62
-$0.04(-14.25%)
Day’s Range― - ―
52-Week Range$1.06 - $5.50
Previous CloseN/A
Volume11.48M
Average Volume (3M)155.08K
Market Cap
$14.34M
Enterprise Value$7.43M
Total Cash (Recent Filing)$24.67M
Total Debt (Recent Filing)$17.01M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Jul 30, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.80
Shares Outstanding11,475,000
10 Day Avg. Volume177,201
30 Day Avg. Volume155,079
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.19
Price to Sales (P/S)0.29
P/FCF Ratio-0.51
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue0.26
Enterprise Value/Gross Profit0.55
Enterprise Value/Ebitda-0.32
Forecast
1Y Price Target
$5.00Price Target Upside208.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.6
Revenue Forecast (FY)$33.54M
Bulls Say, Bears Say
Bulls Say
Consumables & Installed-base Pull-throughRecurring consumables growth (+20% YoY) indicates stronger installed-base utilization and creates a more predictable, annuity-like revenue stream. Durable consumables pull-through scales with instrument placements, supporting revenue stability and margin leverage as adoption broadens over months.
Improving Gross MarginA near-term margin uplift to 49% reflects favorable revenue mix and operational efficiencies. If sustained, it materially reduces the revenue required for profitability and improves cash conversion dynamics, making margin progress a durable structural tailwind as consumables scale.
Balance Sheet Simplification (debt Retirement)Eliminating secured convertible debt removes restrictive covenants and liens, increasing financial flexibility. This structural move lowers refinancing and covenant risk, enabling capital to be redirected toward commercial expansion and execution without secured-debt overhang over the medium term.
Bears Say
Shrinking Revenue & Weak ProfitabilityMaterial revenue decline and deeply negative operating margins signal the business remains far from scale economics. Structural profitability is contingent on sustained top-line recovery and mix shift; until then, continued losses erode equity and constrain reinvestment into sales, R&D, and commercialization.
Persistent Negative Free Cash FlowChronic negative FCF implies ongoing reliance on external financing to fund operations. Even with improved margins, cash burn and limited runway (management cites runway into 2027) create execution risk, forcing potential dilutive raises or spending cuts before a sustainable self-funding position is achieved.
Revenue Lumpiness & Software VolatilityDependence on occasional large software deals creates quarter-to-quarter variability that undermines revenue predictability. This structural lumpiness complicates operational planning, hinders steady consumables attach-rate projections, and raises the risk of funding gaps during weak software-sale periods.
BioNano Genomics News
BNGO FAQ
What was Bionano Genomics’s price range in the past 12 months?
Bionano Genomics lowest stock price was $1.06 and its highest was $5.50 in the past 12 months.
What is Bionano Genomics’s market cap?
Bionano Genomics’s market cap is $14.34M.
When is Bionano Genomics’s upcoming earnings report date?
Bionano Genomics’s upcoming earnings report date is Jul 30, 2026 which is in 60 days.
How were Bionano Genomics’s earnings last quarter?
Bionano Genomics released its earnings results on May 13, 2026. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$0.88 by $0.12.
Is Bionano Genomics overvalued?
According to Wall Street analysts Bionano Genomics’s price is currently Undervalued.
Does Bionano Genomics pay dividends?
Bionano Genomics does not currently pay dividends.
What is Bionano Genomics’s EPS estimate?
Bionano Genomics’s EPS estimate is -0.69.
How many shares outstanding does Bionano Genomics have?
Bionano Genomics has 11,475,000 shares outstanding.
What happened to Bionano Genomics’s price movement after its last earnings report?
Bionano Genomics reported an EPS of -$0.76 in its last earnings report, beating expectations of -$0.88. Following the earnings report the stock price went down -4.8%.
Which hedge fund is a major shareholder of Bionano Genomics?
Currently, no hedge funds are holding shares in BNGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bionano Genomics
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
BNGO Company Deck
BNGO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple positive operational and commercial developments: record Q1 flow cell unit sales, strong consumables growth, improved adjusted gross margin (49% vs 46% YoY), meaningful reimbursement wins that materially improve test economics, growing publication and clinical validation momentum, and balance sheet simplification through planned debt retirement. Offsetting these positives are continued revenue lumpiness (notably a 40% decline in software revenue due to a prior large sale), ongoing supply constraints that are improving, increased operating expenses ($9.1M vs $8.5M YoY) and a cash runway into 2027 with management not expecting cash flow breakeven in 2026. Overall, the call portrays improving commercialization traction and margin progress with material near-term financial and execution risks that management is addressing.View all BNGO earnings summariesBNGO Stock 12 Month Forecast
Average Price Target
$5.00
▲(208.64% Upside)
Technical Analysis
Ownership Overview
1.68% Insiders
1.17% Mutual Funds
0.61% Other Institutional Investors
95.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---